First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors

计划入组 206 人 · 首次发布于 2012 年 6 月 1 日

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

计划入组 110 人 · 首次发布于 2024 年 11 月 12 日

Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC

首次发布于 2017 年 2 月 7 日

Mirvetuximab soravtansine(Elahere)

Mirvetuximab

soravtansine

JINNAH HOSPITAL LAHORE

Pakistan

LAHORE GENERAL HOSPITAL

Pakistan

THE UNIVERSITY OF LAHORE

Pakistan

CHMP Recommends Mirvetuximab Soravtansine (ELAHERE®) for Platinum-Resistant Ovarian Cancer

European Commission Approves AbbVie's Elahere for Platinum-Resistant Ovarian Cancer

European Commission Approves AbbVie's Elahere for Platinum-Resistant Ovarian Cancer